Efficacy of a Zn-based metalorganic framework doped with benznidazole on acute experimental Trypanosoma cruzi infection
Drug Delivery and Translational Research · 2025
DOI: 10.1007/s13346-024-01664-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Delivery and Translational Research, 2025. Verfasst von Anahí Sosa-Arroniz und 5 weiteren Autor:innen. Beteiligte Einrichtung: LADISER, Inmunología y Biología Molecular, Edificio D, Facultad de Ciencias Químicas, Universidad Veracruzana (UV), Prolongación de Oriente 6 #1009; …. Hauptthemen laut MEDLINE: Chagas Disease, Metal-Organic Frameworks, Nitroimidazoles, Zinc. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 61 Literaturangaben.
Abstract (Originalsprache)
Metal-Organic Frameworks (MOFs) have been shown to enhance the activity of encapsulated compounds by facilitating their passage across cell membranes, thereby enabling controlled and selective release. This study investigates the efficacy of BNZ@Zn-MOFs against the acute phase of Trypanosoma cruzi infection in a mouse model. The particles were synthesized by electroelution (EL), doped with BZN via mechanochemistry, and characterized using scanning electron microscopy (SEM), infrared spectroscopy (FTIR), and X-ray diffraction (XRD). BNZ@Zn-MOFs released 80% of the encapsulated BZN within 3 h, demonstrating no cytotoxicity in NIH-3T3 and HeLa cells. Furthermore, in a model of acute experimental T. cruzi-infection in BALB/c mice, the delivery system exhibited antiparasitic activity at a significantly lower BZN concentration compared to free BZN treatment. PCR analysis of treated mice revealed no parasite DNA in their tissues, and hematoxylin-eosin staining showed no apparent damage to tissue architecture. Additionally, serum levels of liver function enzymes remained unchanged, indicating no adverse effects on liver function. This delivery system, utilizing suboptimal BZN doses, enables the preservation of drug activity while potentially facilitating a substantial decrease in side effects associated with Chagas disease treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- LADISER, Inmunología y Biología Molecular, Edificio D, Facultad de Ciencias Químicas, Universidad Veracruzana (UV), Prolongación de Oriente 6 #1009; Colonia Rafael Alvarado; C.P., Orizaba, 94340, Veracruz, México.
- Maestría en Ciencias en Procesos Biológicos, Facultad de Ciencias Químicas, Universidad Veracruzana, Orizaba, 94340, Veracruz, México.
- Asociacion Chagas con Ciencia y Conocimiento A.C., Orizaba, 94390, Veracruz, México.
- LADISER Química Órganica, Facultad de Ciencias Químicas, Universidad Veracruzana, Orizaba, 94340, Veracruz, México.
- LADISER, Inmunología y Biología Molecular, Edificio D, Facultad de Ciencias Químicas, Universidad Veracruzana (UV), Prolongación de Oriente 6 #1009; Colonia Rafael Alvarado; C.P., Orizaba, 94340, Veracruz, México. angra…
- Asociacion Chagas con Ciencia y Conocimiento A.C., Orizaba, 94390, Veracruz, México. angramos@uv.mx.
Zitieren
APA
Sosa-Arroniz, A., López-Monteon, A., Peña-Rodríguez, R., Rivera-Villanueva, J. M., Torres-Montero, J., & Ramos-Ligonio, A. (2025). Efficacy of a Zn-based metalorganic framework doped with benznidazole on acute experimental Trypanosoma cruzi infection. Drug Delivery and Translational Research. https://doi.org/10.1007/s13346-024-01664-0
Vancouver
Sosa-Arroniz A, López-Monteon A, Peña-Rodríguez R, Rivera-Villanueva JM, Torres-Montero J, Ramos-Ligonio A. Efficacy of a Zn-based metalorganic framework doped with benznidazole on acute experimental Trypanosoma cruzi infection. Drug Delivery and Translational Research. 2025. doi:10.1007/s13346-024-01664-0
BibTeX
@article{SosaArroniz2025,
author = {Sosa-Arroniz, Anahí and López-Monteon, Aracely and Peña-Rodríguez, Rodolfo and Rivera-Villanueva, José María and Torres-Montero, Jesus and Ramos-Ligonio, Angel},
title = {Efficacy of a Zn-based metalorganic framework doped with benznidazole on acute experimental Trypanosoma cruzi infection},
journal = {Drug Delivery and Translational Research},
year = {2025},
doi = {10.1007/s13346-024-01664-0}
}
EUVIMED